Chongqing Aisaikang Biotechnology Co., Ltd. (hereinafter referred to as "the Company") is a drug research and operation company with strong R&D capabilities. The company is committed to becoming an excellent and reliable manufacturer and supplier of active pharmaceutical ingredients; it mainly focuses on the research and operation of drugs for anemia, especially iron deficiency anemia, while also paying special attention to medications for diseases affecting middle-aged and elderly people and gynecological diseases, including cardiovascular diseases, diabetes, cancer, endometriosis, and uterine fibroids. The company has completed Delafloxacin Meglumine and Tedizolid Phosphate.

On the morning of July 5, Wu Hongyun, Chairman of Chongqing Aisecang Biotechnology Co., Ltd., and his delegation visited Yuechi to discuss investment matters related to the research, development, and production of active pharmaceutical ingredients. Officials from the local County Investment Promotion Bureau and the County Economic Development Zone accompanied them. Wu Hongyun's delegation focused on inspecting Ren'an Pharmaceutical, distributed natural gas energy, the Economic Development Zone sewage treatment plant, and the proposed land plots. They also gained detailed understanding of the project entry procedures and the park's environmental impact assessment planning. Wu Hongyun stated that the County Economic Development Zone has complete infrastructure and professional supporting facilities. They will further strengthen communication with Yuechi and hope the project can be established in Yuechi as soon as possible.